<DOC>
	<DOCNO>NCT02929576</DOCNO>
	<brief_summary>The purpose study evaluate compare clinical benefit safety treatment enzalutamide combination paclitaxel chemotherapy monotherapy versus placebo paclitaxel patient locally advanced metastatic , diagnostic-positive , triple-negative breast cancer ( TNBC ) .</brief_summary>
	<brief_title>Efficacy Safety Study Enzalutamide Combination With Paclitaxel Chemotherapy Monotherapy Versus Placebo With Paclitaxel Patients With Advanced , Diagnostic-Positive , Triple-Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Adult woman men least 18 year age willing able provide inform consent . Has advance TNBC : TNBC define stain immunohistochemistry ( IHC ) &lt; 1 % Allred score &lt; 2 estrogen receptor ( ER ) progesterone receptor ( PgR ) , 0 1+ IHC human epidermal growth factor receptor 2 ( HER2 ) negative gene amplification ( average HER2 copy number &lt; 4 signals/cell ; HER2 : CEP17 ratio &lt; 2.0 ) . Advanced disease define locally advanced metastatic disease amenable curative intent surgery radiotherapy . Has diagnosticpositive status determine central diagnostic test laboratory . Received 0 1 prior line systemic therapy advance disease set . Patients receive 1 prior line therapy locally advance metastatic TNBC must objective disease progression assess investigator . Has measurable and/or disease measurable evaluable use RECIST 1.1 ( eg , bone metastasis , pathologic lymph node , skin lesion ) . Patients nonmeasurable nonevaluable TNBC ( eg , malignant effusion bone marrow manifestation disease ) eligible enrollment . Patients metastatic disease limit bone must disease adequately visualize compute tomography ( CT ) bone window , magnetic resonance imaging ( MRI ) , xray . Has Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 screen life expectancy least 3 month randomization . Received taxane regimen ≥ 28 day duration advance disease setting . Prior taxane therapy neoadjuvant and/or adjuvant disease permit . A single dose taxane give part every3weeks regimen permit . Two dos taxane give part onceweekly regimen permit . Had diseasefree interval ≤ 12 month last dose taxane use part adjuvant therapy patient receive prior therapy locally advance metastatic breast cancer . Has history know central nervous system ( CNS ) metastasis active leptomeningeal disease ; brain imaging required patient screen . Received anticancer agent ( commercially available investigational ) within 14 day randomization . Received treatment follow medication within 14 day randomization : Estrogens , include hormone replacement therapy Androgens ( eg , testosterone , dehydroepiandrosterone ) Systemic radionuclides ( eg , samarium , strontium ) Had major surgery within 4 week randomization . Has history another invasive cancer within 3 year randomization , exception fully treat cancer remote probability recurrence . Has history seizure condition condition may predispose seizure ( eg , prior cortical stroke significant brain trauma ) . Has know hypersensitivity enzalutamide/placebo capsule component . Had hypersensitivity reaction Cremophor EL ( polyoxyethylated castor oil ) drug formulate Cremophor EL , paclitaxel , unless successfully treat rechallenged appropriate premedications .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>triple negative</keyword>
</DOC>